MCK

McKesson Corporation (MCK) - Q3 2025 (Ended Dec 31, 2024) Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the third quarter and first nine months of McKesson Corporation's fiscal year 2025, ended December 31, 2024. McKesson is a diversified healthcare services leader operating through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The reporting period includes the completion of the sale of the Canadian retail disposal group (Rexall and Well.ca) on December 30, 2024, and the announcement of a definitive agreement to acquire PRISM Vision Holdings.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 18% in Q3 and 15% YTD, driven primarily by market growth in the U.S. Pharmaceutical segment (higher volumes from retail national accounts and specialty pharmaceuticals) and the International segment.
• Profitability: Operating income surged 91% in Q3 ($1,224M vs $642M) due to a $515M bad debt provision in the prior year related to Rite Aid's bankruptcy, which was reversed/credited in the current period ($203M credit YTD). YTD operating income increased 5%.
• Canadian Divestiture: The sale of the Canadian retail disposal group resulted in a $666 million charge to remeasure assets to fair value less costs to sell, significantly impacting the International segment's operating profit (turning a profit into a $307M loss YTD).
• Restructuring: The company recorded $213 million in restructuring charges YTD (vs $84 million prior year) related to enterprise-wide initiatives to modernize technology and streamline operations.
• Liquidity: Operating cash flow turned negative YTD ($(1,663)M) compared to positive $167M in the prior year, primarily due to increases in receivables ($4.1B) and inventories ($3.1B) driven by higher sales volumes and timing.

Guidance, Outlook, and Risks

• Restructuring Outlook: Management anticipates total charges of $650 million to $700 million for current restructuring initiatives, expected to be substantially complete by fiscal 2028.
• Capital Allocation: The company returned $3.1 billion to shareholders YTD via $2.8 billion in share repurchases and $254 million in dividends. The Board increased the repurchase authorization by $4.0 billion in July 2024, leaving $7.8 billion remaining. The quarterly dividend was raised to $0.71 per share.
• Acquisitions: Announced agreements to acquire PRISM Vision Holdings (80% interest, ~$850M) and previously announced Core Ventures (70% interest, ~$2.49B), subject to regulatory clearance.
• Key Risks:
  • Opioid Litigation: Total estimated liability is $6.4 billion. A jury verdict in Baltimore assessed ~$192 million in damages; the company is appealing and has not adjusted reserves. Settlement payments of $500 million were made YTD.
  • Regulatory: Ongoing FTC review of the Core Ventures acquisition.
  • Market Volatility: Exposure to foreign currency fluctuations and interest rate changes, though hedging programs are in place.

Investor Verification Checklist

• Verify the impact of the $666 million Canadian divestiture charge on the International segment's future comparability.
• Monitor the status of the Baltimore opioid litigation verdict and potential appeal outcomes.
• Track the progress of regulatory approvals for the PRISM Vision and Core Ventures acquisitions.
• Assess the sustainability of operating cash flow given the significant working capital build-up (receivables and inventory) YTD.
• Review the timeline and cost realization of the $650M-$700M restructuring initiative.